WO2000042179A3 - Komplexbildende proteine - Google Patents

Komplexbildende proteine Download PDF

Info

Publication number
WO2000042179A3
WO2000042179A3 PCT/EP2000/000029 EP0000029W WO0042179A3 WO 2000042179 A3 WO2000042179 A3 WO 2000042179A3 EP 0000029 W EP0000029 W EP 0000029W WO 0042179 A3 WO0042179 A3 WO 0042179A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimerization domain
component
mutated
complex
mutated dimerization
Prior art date
Application number
PCT/EP2000/000029
Other languages
English (en)
French (fr)
Other versions
WO2000042179A2 (de
Inventor
Valerie Jerome
Hans-Harald Sedlacek
Rolf Mueller
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Priority to KR1020017008779A priority Critical patent/KR20010089817A/ko
Priority to JP2000593736A priority patent/JP2002534121A/ja
Priority to CA002359479A priority patent/CA2359479A1/en
Priority to EP00906186A priority patent/EP1144634A2/de
Priority to AU27960/00A priority patent/AU2796000A/en
Priority to MXPA01006988A priority patent/MXPA01006988A/es
Publication of WO2000042179A2 publication Critical patent/WO2000042179A2/de
Publication of WO2000042179A3 publication Critical patent/WO2000042179A3/de
Priority to HK02104074.9A priority patent/HK1042520A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

Die Erfindung bezieht sich auf einen Komplex aus nicht natürlich vorkommenden, spezifisch komplexbildenden Proteinen enthaltend folgende Komponenten: a) mindestens ein für eine Zielstruktur spezifischer Ligand, b) mindestens ein Protein enthaltend eine mutierte Dimerisierungsdomäne, wobei die mutierte Dimerisierungsdomäne durch Mutierung von einer natürlich vorkommenden Dimerisierungsdomäne abgeleitet worden ist, diese mutierte Dimerisierungsdomäne spezifisch mit Komponente c) wechselwirken kann und die Komponente b) kovalent mit der Komponente a) verbunden ist, c) mindestens ein Protein enthaltend eine mutierte Dimerisierungsdomäne, wobei die mutierte Dimerisierungsdomäne durch Mutierung von einer natürlich vorkommenden Dimerisierungsdomäne abgeleitet worden ist, diese mutierte Dimerisierungsdomäne spezifisch mit Komponente b) wechselwirken kann und die Komponente c) kovalent mit der Komponente d) verbunden ist, und d) mindestens einen Effektor. Desweiteren bezieht sich die Erfindung auf die Verwendung und Herstellung dieser Komplexe sowie Nukleinsäurekonstrukte kodierend für die genannten Proteine und deren Verwendung.
PCT/EP2000/000029 1999-01-12 2000-01-05 Komplexbildende proteine WO2000042179A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020017008779A KR20010089817A (ko) 1999-01-12 2000-01-05 복합체-형성 단백질
JP2000593736A JP2002534121A (ja) 1999-01-12 2000-01-05 新規な複合体形成タンパク質
CA002359479A CA2359479A1 (en) 1999-01-12 2000-01-05 Novel complex-forming proteins
EP00906186A EP1144634A2 (de) 1999-01-12 2000-01-05 Komplexbildende proteine
AU27960/00A AU2796000A (en) 1999-01-12 2000-01-05 Novel complex-forming proteins
MXPA01006988A MXPA01006988A (es) 1999-01-12 2000-01-05 Proteinas que forman complejo novedosas.
HK02104074.9A HK1042520A1 (zh) 1999-01-12 2002-05-31 新型復合物形成蛋白質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900743A DE19900743A1 (de) 1999-01-12 1999-01-12 Neue komplexbildende Proteine
DE19900743.8 1999-01-12

Publications (2)

Publication Number Publication Date
WO2000042179A2 WO2000042179A2 (de) 2000-07-20
WO2000042179A3 true WO2000042179A3 (de) 2000-11-16

Family

ID=7893962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000029 WO2000042179A2 (de) 1999-01-12 2000-01-05 Komplexbildende proteine

Country Status (12)

Country Link
US (2) US6495346B1 (de)
EP (1) EP1144634A2 (de)
JP (1) JP2002534121A (de)
KR (1) KR20010089817A (de)
CN (1) CN1340103A (de)
AU (1) AU2796000A (de)
CA (1) CA2359479A1 (de)
DE (1) DE19900743A1 (de)
HK (1) HK1042520A1 (de)
MX (1) MXPA01006988A (de)
WO (1) WO2000042179A2 (de)
ZA (1) ZA200105427B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100474114B1 (ko) * 2001-12-24 2005-03-08 대한민국 소 타일레리아병에 대한 면역원성이 증진된 융합단백질, 및 그의 제조방법 및 용도
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
WO2004015083A2 (en) * 2002-08-08 2004-02-19 Insert Therapeutics, Inc. Compositions and uses of motor protein-binding moieties
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CA2772610C (en) * 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
EA020171B1 (ru) * 2009-11-09 2014-09-30 Илья Валерьевич ТИМОФЕЕВ Слитый белок, содержащий фактор роста фибробластов или его фрагмент и рецептор фактора роста фибробластов или его фрагмент, и применение белка для лечения или профилактики заболеваний или состояний, связанных с патологией сосудов
RU2486918C1 (ru) * 2011-10-25 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций
RU2538621C2 (ru) * 2013-05-08 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ стимулирования восстановления иннервации тканей после травм и ишемии с помощью векторной конструкции
CN113150086B (zh) * 2021-04-22 2022-10-11 成都欧林生物科技股份有限公司 幽门螺杆菌HefC重组蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805209A2 (de) * 1996-05-03 1997-11-05 Hoechst Aktiengesellschaft Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
US6110698A (en) * 1996-05-31 2000-08-29 American Cyanamid Company Screen for ultraspiracle inhibitors
DE19710643A1 (de) 1997-03-14 1998-09-17 Hoechst Ag Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805209A2 (de) * 1996-05-03 1997-11-05 Hoechst Aktiengesellschaft Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHYTIL M ET AL: "The orientation of the AP-1 heterodimer on DNA strongly affects transcription potency", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, no. 24, 24 November 1998 (1998-11-24), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 14076 - 14081, XP002142300, ISSN: 0027-8424 *
JERÔME V ET AL: "Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells", HUMAN GENE THERAPY, vol. 9, no. 18, 10 December 1998 (1998-12-10), ISSN:1043-0342, pages 2653 - 2659, XP000915434 *
WANG Y ET AL: "A regulatory system for use in gene transfer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 91, August 1994 (1994-08-01), pages 8180 - 8184, XP002121654, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1144634A2 (de) 2001-10-17
JP2002534121A (ja) 2002-10-15
US6495346B1 (en) 2002-12-17
CN1340103A (zh) 2002-03-13
US20030054409A1 (en) 2003-03-20
HK1042520A1 (zh) 2002-08-16
DE19900743A1 (de) 2000-07-13
AU2796000A (en) 2000-08-01
MXPA01006988A (es) 2002-04-24
ZA200105427B (en) 2002-07-16
CA2359479A1 (en) 2000-07-20
KR20010089817A (ko) 2001-10-08
WO2000042179A2 (de) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2000042179A3 (de) Komplexbildende proteine
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
UA97473C2 (ru) Выделенное антитело, которое связывается с her-3, и его применение
AU7542398A (en) Nucleic acid binding proteins
EP1690872A3 (de) Zusammensetzung und Verfahren zur Diagnose eines Tumors
WO1994025477A3 (en) Novel peptide nucleic acids
AU7381098A (en) Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
WO2002055718A3 (en) Assembly and screening of highly complex and fully human antibody repertoire in yeast
AU5060900A (en) Chemically modified lipolytic enzyme
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2003046200A3 (en) Methods for ligand discovery
WO2002024912A3 (en) Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
AU1172202A (en) Far red shifted fluorescent proteins
WO2002012290A8 (en) Sid polypeptides binding to pathogenic strain of the hepatitis c virus
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
PT1368491E (pt) Processo para a selecção, por separação bidimensional, de ácidos nucleicos que se ligam com elevada afinidade a um alvo
WO2002068459A3 (en) Non aggregating fluorescent proteins and methods for using the same
Yang et al. Characterization of Purified c-Type Heme-Containing Peptides and Identification of c-Type Heme-Attachment Sites in Shewanella o neidenis Cytochromes Using Mass Spectrometry
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
WO2005049639A3 (en) Compositions and methods for protein isolation
WO2000028043A3 (en) Polypeptides having lactonohydrolase activity and nucleic acids encoding same
WO2000077031A3 (en) Muc1 ligands
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00803763.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/05427

Country of ref document: ZA

Ref document number: 200105427

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000906186

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006988

Country of ref document: MX

Ref document number: 27960/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2359479

Country of ref document: CA

Ref document number: 2359479

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 593736

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017008779

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020017008779

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000906186

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000906186

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017008779

Country of ref document: KR